This dataset contains image annotations derived from "The Clinical Proteomic Tumor Analysis Consortium Pancreatic Ductal Adenocarcinoma Collection (CPTAC-PDA)”.  This dataset was generated as part of a National Cancer Institute project to augment images from The Cancer Imaging Archive with annotations that will improve their value for cancer researchers and artificial intelligence experts.

Annotation Protocol

For each patient, all scans were reviewed to identify and annotate the clinically relevant time points and sequences/series. In a typical patient all available time points were annotated. The following annotation rules were followed:

1. PERCIST criteria was followed for PET imaging. Specifically, the lesions estimated to have the most elevated SUVmax were annotated.
2. RECIST 1.1 was otherwise generally followed for MR and CT imaging. A maximum of 5 lesions were annotated per patient scan (timepoint); no more than 2 per organ. The same 5 lesions were annotated at each time point. Lymph nodes were annotated if >1 cm in short axis. Other lesions were annotated if >1 cm. If the primary lesion measures < 1 cm, it was still annotated.
3. Lesions were annotated in the axial plane. If no axial plane was available, lesions were annotated in the coronal plane.
4. MRIs were annotated using axial T1-weighted post contrast sequences that best demonstrated the tumor.
5. CTs were annotated using all axial post contrast series’. If not available, the axial non-contrast series were annotated.
6. Lesions were labeled separately.
7. Seed points were automatically generated but reviewed by a radiologist.
8. A “negative” annotation wascreated for any exam without findings.
9. PET/CTs were annotated on the CT and attenuation corrected PET images, unless there was a diagnostic CT from the same time point, in which case the CT portion of the PET/CT was not be annotated.

At each time point:

1. A seed point (kernel) was created for each segmented structure. The seed points for each segmentation are provided in a separate DICOM RTSTRUCT file.
2. SNOMED-CT “Anatomic Region Sequence” and “Segmented Property Category Code Sequence” and codes were inserted for all segmented structures
3. Imaging time point codes were inserted to help identify each annotation in the context of the clinical trial assessment protocol.
   1. “Clinical Trial Time Point ID” was used to encode time point type using one of the following strings as applicable: “pre-dose” or “post-chemotherapy”
   2. Content Item in “Acquisition Context Sequence” was added containing "Time Point Type" using Concept Code Sequence (0040,A168) selected from:
      1. (255235001, SCT, “Pre-dose”)
      2. (719864002, SCT, "Post-cancer treatment monitoring")